Page last updated: 2024-11-06

xibornol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

xibornol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

xibornol : A bridged compound that is 3,4-xylenol carrying an additional isobornyl substituent at position 6. A lipophilic antibacterial drug mainly used in spray dosage forms for the local treatment of infection and inflammation of the throat. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11777299
CHEMBL ID2104519
SCHEMBL ID151864
MeSH IDM0044892

Synonyms (13)

Synonym
xibornol
6-isobornyl-3,4-xylenol
13741-18-9
CHEMBL2104519
phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-
34632-99-0
SCHEMBL151864
DTXSID60472406
4,5-dimethyl-2-[(1r,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl]phenol
Q4021823
3,4-xylenol, 6-isobornyl- (8ci)
4,5-dimethyl-2-(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)phenol
bactacine; nanbacine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Xibornol is a lipophilic drug mainly used in Italy and Spain in spray dosage forms for the local treatment of infection and inflammation of the throat."( Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri, M; Mora, PC; Mura, P, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (77.78)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's0 (0.00)24.3611
2020's2 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (35.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (65.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]